The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008Identification of binding proteins for alpha-synuclein oligomers in brain and cells
Mutations in the PARK-1 and PARK-4 genes leads to alpha-synuclein aggregation with pathology eventually resembling that of sporadic PD. One question is whether the insoluble form of alpha-synuclein is...
-
Rapid Response Innovation Awards, 2008The Glucosylceramide Pathway in Parkinson's Disease and other Synucleinopathies: Genetic defects, Neuropathological characterization and cell culture models
Objective/Rationale:
Mutations in the beta glucocerebrosidase (GBA) gene are associated with Parkinson’s disease. Only a small number of neuropathologically confirmed PD, multiple system atrophy (MSA)... -
Rapid Response Innovation Awards, 2008Neuronal Nicotinic Acetylcholine Receptor Upregulation for the Treatment of Parkinson's Disease
Objective/Rationale:
Many studies demonstrate an inverse correlation between tobacco use and the risk of Parkinson’s disease. This inadvertent therapeutic effect of tobacco may be caused by the... -
Rapid Response Innovation Awards, 2008Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1
Objective/Rationale:
Our laboratory has recently shown that a genetic variant of the gene UCH-L1, associated with reduced risk for Parkinson’s disease, specifically prevents the generation of damaging... -
Rapid Response Innovation Awards, 2008Multimodal assessment of gastric motility in subjects at (pre)clinical stages of Parkinson´s Disease - A pathohistological and functional in-vivo-testing of Braak's pathoanatomical model
Objective/Rationale:
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a sleep disorder that presents with dream-enactments (vigorous movements, speech) during REM sleep. Patients with RBD... -
Rapid Response Innovation Awards, 2008MicroRNA regulation of aSynuclein as a drug target
Objective/Rationale:
A central hypothesis for Parkinson’s pathology is that excessive alpha-Synuclein protein, most likely in the form of aggregates, is toxic to midbrain dopamine neurons. Our prior...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.